Treatment of dysfunctional uterine bleeding in the perimenopause: The effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment - A randomized, placebo-controlled, double-blind trial

Gynecological Endocrinology

Volumn 22, Issue 12, 2006, Pages 692-697

  Franke, Henk R ^a   Snaaijer, F Froukje ^b   Houben, Paul W H ^c   Van Der Mooren, Marius J ^d  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b WALSGRAVE HOSPITAL   (United Kingdom)

^c Location Alkmaar   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone mineral density; Dysfunctional uterine bleeding; Estradiol norethisterone acetate; Goserelin acetate; Mammographic density; Randomized placebo controlled trial

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; GOSERELIN; PLACEBO;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ARTICLE; BONE DENSITY; CHEMOPROPHYLAXIS; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOMETRIUM; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAMMOGRAPHY; MENOPAUSAL SYNDROME; METRORRHAGIA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OSTEOLYSIS; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; THICKNESS; TREATMENT DURATION; VAGINA BLEEDING; VISUAL ANALOG SCALE; WELLBEING;

ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; CLIMACTERIC; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ESTRADIOL; FEMALE; GOSERELIN; HORMONE REPLACEMENT THERAPY; HUMANS; MAMMOGRAPHY; METRORRHAGIA; MIDDLE AGED; NORETHINDRONE; PERIMENOPAUSE;

EID: 33845639197     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590601015101     Document Type: Article

References (22)

1. Bayer SR, DeCherney AH. Clinical manifestations and treatment of dysfunctional uterine bleeding. J Am Med Assoc 1993;269:1823-1828.
2. Kitawaki J, Kado N, Ishihara H, Koshiba H, Kiataoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol 2002;83:149-155.
3. McLachlan RI, Healy DL, Burger HG. Clinical aspects of LHRH analogues in gynaecology: a review. Br J Obstet Gynaecol 1986;83:431-454.
4. Shaw RW. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Fertil Steril 1992;58:265-272.
5. Reichel RP, Schweppe KW. Goserelin (Zoladex) depot in the treatment of endometriosis. Zoladex Endometriosis Study Group. Fertil Steril 1992;57:1197-1202.
6. Miller RM, Frank RA. Zoladex (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy. Br J Obstet Gynaecol 1992;99:37-41.
7. Edmonds DK, Howell R. Can hormone replacement therapy be used during medical therapy of endometriosis? Br J Obest Gynaecol 1994;101(Suppl 10):24-26.
8. Lindsay PC, Shaw RW, Bennink HJ, Kicovic CP. The effect of add-back treatment with tibolone (Livial) on patients treated with gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 1996;65:342-348.
9. Compston JE, Yamaguchi K, Groucher PI, Lindsay PC, Shaw RW. The effects of gonadotropin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1995;16:261-267.
10. Paoletti AM, Serra GG, Cagnacci A, Vacca AM, Guerriero S, Solla E, Mellis GB. Spontaneous reversibility of bone loss induced by gonadotropin releasing hormone analogue treatment. Fertil Steril 1996;65:707-710.
11. Schlaff WD. Extending the treatment boundaries: Zoladex and add-back. Int J Gynaecol Obstet 1999;64:25-31.
12. Franke HR, van de Weijer PHM, Pennings TMM, van der Mooren MJ. Gonadotropin-releasing hormone agonist plus 'add-back' hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril 2000;74:534-539.
13. Segura C, Avenin D, Gligorov J, Esteso A, Beerblock K, Emile G, Do Huyen N, Lotz JP. The use of GnRH analogues in early and advanced breast carcinomas. Gynecol Obstet Fertil 2005;33:914-919.
14. Gram IT, Ursin G, Spicer DV, Pike MC. Reversal of GnRH agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol Biomarkers Prev 2001;10:1117-1120.
15. Barbieri R. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740-745.
16. Van Gorp T, Neven P. Endometrial safety of hormonal replacement therapy: review of the literature. Maturitas 2002;42:93-104.
17. Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25-31.
18. Mendez A, Cabanillas F, Echenique M, Malekshamram K, Perez I, Ramos E. Mammographic features and correlation with biopsy findings using 11-gauge stereotactic vacuum-assisted breast biopsy (SVABB). Ann Oncol 2004;15:450-454.
19. Sagsveen M, Farmer JF, Prentice A, Breeze A. Cochrane review of gonadotrophin-releasing hormone analogues for endometriosis; bone mineral density. Cochrane Database Syst Rev 2003;(4):CD001297.
20. Pierce SJ, Gazvani CBM, Farquharson RG. Long-term use of GnRH analogs and hormone replacement therapy in the management of endometriosis; a randomized trial with a 6 year follow-up. Fertil Steril 2000;74:964-968.
21. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, et al., WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. J Am Med Assoc 2003;289:3243-3253.
22. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95: 30-37.